![Michael Halpin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Halpin
Directeur des opérations chez
VERICEL CORPORATION
Fortune : 753 468 $ au 31/07/2026
Profil
Michael Halpin is currently Chief Operating Officer at Vericel Corp.
since 2019.
Formerly, Mr. Halpin was Vice President-North American Region Regulatory at Genzyme Corp.
from 2002 to 2017 and held the same title at Sanofi Corp.
Education includes undergraduate and graduate degrees from the University of Virginia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERICEL CORPORATION 0,03% | 03/08/2026 | 16 394 ( 0,03% ) | 753 468 $ | 31/07/2026 |
Postes actifs de Michael Halpin
| Sociétés | Poste | Début |
|---|---|---|
| VERICEL CORPORATION | Directeur des opérations | 15/06/2019 |
Anciens postes connus de Michael Halpin
| Sociétés | Poste | Fin |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Conseiller Juridique Général | - |
Sanofi Corp.
 Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Corporate Officer/Principal | - |
Formation de Michael Halpin
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Vericel Corp.
 Vericel Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures and markets two advanced cell therapy products for sports medicine and severe burn care | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
University of Virginia
 University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Corp.
Sanofi Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi Corp. is a biopharmaceutical company dedicated to improving health outcomes through innovative medicines, vaccines, and patient-centered care. The company is based in Bridgewater, NJ. The company offers a broad portfolio including prescription medicines across therapeutic areas such as immunology, neurology, oncology, rare diseases, cardiovascular disease, diabetes, and transplant, alongside an extensive range of vaccines protecting against infectious diseases like influenza, respiratory syncytial virus (RSV), dengue, and COVID-19. Sanofi emphasizes scientific innovation with a robust R&D pipeline comprising clinical-stage projects, including advanced therapies like bispecific antibodies, gene therapies, and mRNA vaccines. The company addresses complex conditions such as chronic graft-versus-host disease in transplant patients and rare blood disorders like immune thrombocytopenia purpura, having launched therapies in these areas. Sanofi collaborates with healthcare professionals, patient communities, advocacy groups, and governments to expand access, promote holistic care, and advance science. Social impact initiatives focus on health equity, inclusion, environmental factors affecting respiratory health, and responsible business practices. Sanofi provides resources for healthcare providers and patients, including prescribing information, patient support, and educational materials, and maintains transparent communication through media channels and regular updates on financial performance, regulatory approvals, and clinical trial progress. | Health Technology |
